Wyoming Tech Reporter
SEE OTHER BRANDS

Your best source on science and technology news from Wyoming

Wyoming Tech Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wyoming Tech Reporter.

Press releases published on July 25, 2025

Nürburgring chooses vivenu: New partnership accelerates ticketing innovation

Nürburgring chooses vivenu: New partnership accelerates ticketing innovation

DÜSSELDORF, Germany and NÜRBURG, Germany, July 25, 2025 (GLOBE NEWSWIRE) -- Nürburgring, Germany’s largest sporting venue and one of the world’s most iconic racetracks, has selected vivenu as its new ticketing partner. The collaboration marks a strategic …

Where Dawn Breaks and Dreams Take Root: The GEBE Family

Where Dawn Breaks and Dreams Take Root: The GEBE Family

SINGAPORE, July 25, 2025 (GLOBE NEWSWIRE) -- The Early Birds: Nurturing a Legacy from Dawn Before the city fully stirs, while the sky is still painted in hues of early morning, the founder-couple, Toh Kim Tay (Steven Tay) and Gek Hong Toh (Joyce Tay) are …

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union

Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu auftretende Sublinien generierte, einschließlich der XFG- und …

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization …

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the …

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit …

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients  No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to transform the treatment landscape …

Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe

Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe

Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Approbation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ajout de Sarclisa au traitement d’ …

SIMPPLE Ltd. Fully Regains Compliance with Nasdaq’s Continued Listing Requirements

SIMPPLE Ltd. Fully Regains Compliance with Nasdaq’s Continued Listing Requirements

Singapore, July 24, 2025 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management (FM) sector, today announced that it has received notice from The Nasdaq Stock …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions